| CAR T Therapy Induces Response in Majority of Patients With Relapsed Multiple Myeloma |
| Idecabtagene vicleucel induced progression-free survival up to 20 months and a complete response in one-third of patients with multiple myeloma who had relapsed multiple times and had received at least 3 previous lines of treatment. |
| |
|
| |
| D’Angelo Describes Innovative Combos Designed to Produce Durable Activity in Relapsed/Refractory DLBCL |
| Christopher D'Angelo, MD, discusses emerging CAR T-cell therapies in the space, as well as in follicular lymphoma, and the challenges with using a 5-drug regimen. |
| |
|
| |
|
| FDA Grants RP-L201 RMAT Designation for LAD-I |
| The FDA has granted an RMAT designation to RP-L201 as a potential treatment for patients with leukocyte adhesion deficiency-I. |
| |
|
| |
|
| mRNA-Based CAR T-Cell Therapy Descartes-11 Moves Into Phase 2 Trial in Myeloma |
| A phase 2 clinical trial has been initiated to evaluate Descartes-11, an mRNA CAR T-cell therapy, as a consolidative therapy in patients with newly diagnosed, high-risk multiple myeloma who have residual disease after induction therapy. |
| |
|
| |
|
| FDA Grants Valoctocogene Roxaparvovec RMAT Designation for Hemophilia A |
| The FDA has granted an RMAT designation to valoctocogene roxaparvovec for hemophilia A. |
| |
|
| |
|
| AXO-AAV-GM2 Administered to First Patient in GM2 Gangliosidosis Trial |
| The 2-stage study is an open-label, 2-stage clinical trial designed to evaluate safety and dose-escalation (stage 1) and safety and efficacy (stage 2) of surgically delivered AXO-AAV-GM2. |
| |
|
| |
|
| |
| |
|
 |
|
